CSL to Launch Seqirus Spinoff Business Amid Major Restructure

CSL Limited (CSLLY), Australia’s biotech and plasma-therapeutics giant, will spin off its vaccine division, CSL Seqirus, into a separately listed entity by mid-2026. The move comes alongside a sweeping restructuring that includes job cuts, a multibillion-dollar charge, and a substantial share buyback. Seqirus Spinoff Details CSL said it plans to complete the Seqirus spinoff by June 2026, with… Read More »